{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-063667","form_type":"8-K","ticker":"BNTC","cik":"0001808898","company_name":"Benitec Biopharma Inc.","filed_at":"2024-03-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.615941+00:00","generated_at":"2026-06-05T00:41:36.397319+00:00","sec_items":["5.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Benitec Biopharma grants 666,558 stock options to CEO and executive director at $5.21","bullets":["Compensation Committee approved nonqualified options for CEO Jerel Banks (466,554 shares) and Exec. Director Megan Boston (200,004 shares).","Exercise price of $5.21 per share equals March 6, 2024 closing price.","Options vest in three equal annual installments; full acceleration upon change in control.","Grants made under the Company's 2020 Equity and Incentive Compensation Plan."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-063667","json":"https://secwatch.observer/filing/0001193125-24-063667.json","markdown":"https://secwatch.observer/filing/0001193125-24-063667.md","text":"https://secwatch.observer/filing/0001193125-24-063667.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1808898/000119312524063667/0001193125-24-063667-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1808898/000119312524063667/d782153d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T00:41:36.397319+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}